Acquired haemophilia A treated with recombinant factor VIIa by an infusion pump and midline catheter

Abstract

Acquired haemophilia A is an autoimmune bleeding disorder treated with immunosuppression and bypassing agents such as recombinant factor VIIa (rFVIIa). The half time of rFVIIa is short, which requires frequent bolus injections in order to maintain hemostasis. Providing a continuous pump infusion instead of bolus injections could not only be more time and cost-efficient but also safer by maintaining a constant level of the bypassing agent.

rFVIIa is administered intravenously usually through a peripheral venous catheter. In patients with prolonged intravenous treatment or difficult-to-access peripheral vasculature, midline long peripheral intravenous catheters are an interesting alternative. They have favourable dwell times and failure rates while maintaining the same risk of infection as other peripherally inserted central catheters. This technique has the potential to reduce the costs as well as risk to the patients.

Herein, we report a case of a patient with AHA, who was treated with rFVIIa by an infusion pump and midline catheter.